RHEUMATOLOGY INFUSION REFERRAL FORM



PATIENT INFORMATION

Last Name	First Name			DOB
Gender	Last 4 SSN			Primary Language
Address				
City		State		ZIP
Email				
Home Phone	Work Phone			Cell Phone
Primary Contact Method (check one)	□ Cell Phone □ Text □ Em □ DO NOT CO	nail 🗆		ne □Work Phone Caregiver
Primary Caregiver/Alt Contact Name (If applicable)				
Caregiver/Alt Contact Email			Caregi	ver/Alt Contact Phone

PRESCRIBER INFORMATION

Name of Contact Sending Referral		Title
Preferred Contact	Referral Conta	ict Email
Office Phone	Office Fax	
Practice / Facility Name		
Address		
City	State	ZIP
Prescriber Name / Specialty		
Prescriber State License #		DEA #
NPI #		Medicaid UPIN #

INSURANCE INFORMATION

Insurance Provider		Plan ID #
BIN#: PCN#:		RX Group#:
Insured's Name		Relationship to Patient

Eligible for Medicare (check one)	□ Yes □ No	If yes, list Medicare #	
Prescription Card (check one)	□ Yes □ No	lf yes, list carrier	

Please include a copy of the front and back of insurance card.

CLINICAL INFORMATION

Prescription Type	□ Naïve/New Start □ Therapy Restart □ Existing Treatment	Therapy Start Date
Sample/Starter Product Provided? □Yes □No	If yes, Provide Qty	Date Sample Provided
Allergies NKDA Drug Allergies (p	olease list)	
Therapies Tried and Failed (pl	ease list medications)	
Concurrent Medications		

Patient Height (cm/in)		Patient Weight (kg/lbs)	Date Obtained
		ne □Prescriber's Office er (please list)	1
ICD-10 Codes	 M32.9 Other for M32.10 Systemi unspecified M32.19 Other of M05.79 Rheuma organ or system M05.89 Other rh 	neumatoid arthritis with rheum pecified rheumatoid arthritis, n oid Arthritis	atosus, unspecified or system involvement systemic lupis erythematosu factor of multiple sites w/o natoid factor of multiple sites

We accept Escribe and fax prescriptions.

PRESCRIPTIONS

Patient Last Name

Patient First Name

DOB

PRESCRIPTION INFORMATION

MEDICATION	ROUTE	DOSE/STRENGTH	DIRECTIONS	QTY	REFILLS
□ Benlysta	□IV	□ 10 mg/kg	Starting Dose □ 10 mg/kg IV at week 0, 2, 4 and then every weeks Maintenance Dose □ 10 mg/kg IV everyweeks	□ 1 month □ 3 months □	□ 1 year □
🗆 Cimzia	ΠIV	□ 200 mg prefilled syringe □ 200 mg lyophilized powder vial	Starting Dose 400 mg (given as two 200 mg subcutaneous injections) at weeks 0,2 and 4 Maintenance Dose 200 mg subcutaneous injection every other week Other	□ 1 month □ 3 months □	□ 1 year □
□ Orencia (abatacept)	□IV	☐ 500 mg Orencia ☐ 750 mg Orencia ☐ 1000 mg Orencia	□ Infuse over 30 minutes	□ 1 month □ 3 months □	□ 1 year □
□ Remicade (infliximab)	ΠIV	Starting Dose 5 mg/kgmg IV at week 0,2,6 3 mg/kgmg IV at week 0,2,6 Other Maintenance Dose 2 mg/kgmg IV every 8 weeks Other	□ To be infused over a period NOT less than 2 hours	□ 1 month □ 3 months □	□ 1 year □
□Rituxin	□IV	□ 1000 mg IV on day 0, day 14 and then repeat the course everyweeks □ 375 mg/m2 IV every 4 weeks □ Other	□ Infuse as directed	□ 1 month □ 3 months □	□ 1 year □
□ Simponi Aria (golimumab)	ΠIV	Starting dose 2 mg/kgmg IV at week 0, 4 and every 8 weeks Other Maintenance Dose 2 mg/kgmg IV every 8 weeks Other	□ Infuse diluted solution over a period of 30 minutes	□ 1 month □ 3 months □	□ 1 year □

See next page for additional medications.

Patient Support Programs: Please have patient sign and date to enroll in pharmaceutical company assisted support program.

- · · ·	.
Patient	Signature

	/_	1	
Date			

Account Manager

Prescriber Authorization (No stamps. Signature and date must be completed in prescriber's handwriting.)

Prescriber Signature	/ Date
	/
Supervising Physician Signature (Dispense as Written)	Date

**The information contained in this document will become a legal prescription. Follow all state Medical Board guidelines when completing, inclusive of guidelines that pertain to the number of prescriptions allowed on a single prescription form. If more than one page is required, make additional copies. Use state board mandated language for dispensing brand name medications or generic substitution and follow physician signature requirements.

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone number set forth herein and obtain instructions as to proper destruction of the transmitted material.

PRESCRIPTIONS

Patient Last Name

Patient First Name

DOB

PRESCRIPTION INFORMATION

MEDICATION	ROUTE	DOSE/STRENGTH	DIRECTIONS	QTY	REFILLS
□ Normal Saline □ D5W		□ 3 mL □ 5 mL □	□ Before and after infusion □	□ 1 month □ 3 months □	□ 1 year □
□ Heparin 10 units/mL □ Heparin 100 units/mL	ΠIV	□ 3 mL □ 5 mL □	□ After infusion	□ 1 month □ 3 months □	□ 1 year □
□ Diphenhydramine	□ PO □ IV □ IM	□ 25 mg □ 50 mg □	After infusion PRN Allergic Reaction:	□With each infusion □	□ 1 year □
□ Acetaminophen	□PO	□ 325 mg □ 500 mg □ 650 mg □ 1 gm □	□ Pre-Med:	□With each infusion □	□ 1 year □
□Epinephrine	□ IM □ SQ	□ Adult 1:1000, 0.3 mL (>30kg/>66lbs) □ Peds 1:2000, 0.3 mL (15-30kg/33-66lbs)	PRN Anaphylaxis Repeating Dose:	□ Once □	□ 1 year □
□ Other:	□				
□ Vascular Access Method	□ periphe	ral □central □other:			

Total RXs ____

Lab Orders

Skilled nursing visits as needed to establish venous access administer medication and assess general status and response to therapy. Dispense 1 month of drug, flushes, needles, syringes, ancillary supplies and medical equipment necessary to establish access and administer medication. Prescription to include all necessary ancillary supplies (needle, syringes, etc). If shipped to physician's office, physician accepts on behalf of patient for administration in office.

Patient Support Programs: Please have patient sign and date to enroll in pharmaceutical company assisted support program.

D	c
Patient	Signature

	/_	 /_	_
Date			

____/___/___ Date Account Manager

Prescriber Authorization (No stamps. Signature and date must be completed in prescriber's handwriting.)

Prescriber Signature	

**The information contained in this document will become a legal prescription. Follow all state Medical Board guidelines when completing, inclusive of guidelines that pertain to the number of prescriptions allowed on a single prescription form. If more than one page is required, make additional copies. Use state board mandated language for dispensing brand name medications or generic substitution and follow physician signature requirements.

____/__/__ Date

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone number set forth herein and obtain instructions as to proper destruction of the transmitted material.